Zacks Investment Research Lowers Spark Therapeutics, Inc. (ONCE) to Hold
According to Zacks, “Spark Therapeutics, Inc. offers gene therapy. The Company’s product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. “
Other research analysts have also issued reports about the stock. Wedbush reiterated an underperform rating and issued a $28.00 price target on shares of Spark Therapeutics in a research note on Monday, December 5th. Jefferies Group reiterated a hold rating and issued a $57.00 price target on shares of Spark Therapeutics in a research note on Tuesday. BMO Capital Markets began coverage on shares of Spark Therapeutics in a research note on Tuesday, December 20th. They issued an outperform rating and a $69.00 price target for the company. Vetr lowered shares of Spark Therapeutics from a strong-buy rating to a buy rating and set a $62.50 price target for the company. in a research note on Wednesday, January 4th. Finally, Chardan Capital reiterated a neutral rating and issued a $47.50 price target (down from $55.00) on shares of Spark Therapeutics in a research note on Monday, November 7th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of $60.69.
Spark Therapeutics (NASDAQ:ONCE) opened at 57.13 on Friday. The stock’s market capitalization is $1.76 billion. The company’s 50-day moving average is $53.39 and its 200 day moving average is $55.20. Spark Therapeutics has a 12-month low of $21.20 and a 12-month high of $65.99.
Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Thursday, November 3rd. The company reported ($1.07) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.01) by $0.06. Spark Therapeutics had a negative return on equity of 28.28% and a negative net margin of 441.05%. The company earned $1.30 million during the quarter, compared to the consensus estimate of $1.26 million. During the same quarter last year, the company posted ($0.70) earnings per share. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. On average, equities research analysts expect that Spark Therapeutics will post ($4.13) earnings per share for the current fiscal year.
In other news, insider Katherine A. High sold 10,000 shares of the firm’s stock in a transaction dated Monday, November 14th. The shares were sold at an average price of $60.30, for a total transaction of $603,000.00. Following the sale, the insider now owns 210,000 shares of the company’s stock, valued at approximately $12,663,000. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Anand Mehra sold 122,532 shares of the firm’s stock in a transaction dated Tuesday, December 13th. The shares were sold at an average price of $55.17, for a total transaction of $6,760,090.44. The disclosure for this sale can be found here. Insiders own 9.60% of the company’s stock.
Several hedge funds have recently made changes to their positions in ONCE. Teacher Retirement System of Texas increased its stake in shares of Spark Therapeutics by 14.0% in the second quarter. Teacher Retirement System of Texas now owns 2,432 shares of the company’s stock worth $124,000 after buying an additional 299 shares during the last quarter. Legal & General Group Plc increased its stake in shares of Spark Therapeutics by 105.6% in the second quarter. Legal & General Group Plc now owns 2,714 shares of the company’s stock worth $138,000 after buying an additional 1,394 shares during the last quarter. Great West Life Assurance Co. Can increased its stake in shares of Spark Therapeutics by 113.5% in the third quarter. Great West Life Assurance Co. Can now owns 2,675 shares of the company’s stock worth $160,000 after buying an additional 1,422 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Spark Therapeutics during the third quarter worth about $188,000. Finally, Argentus Capital Management LLC bought a new stake in shares of Spark Therapeutics during the third quarter worth about $293,000. 82.98% of the stock is currently owned by hedge funds and other institutional investors.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.